Editorial: an elastography‐based two‐step approach to detect NAFLD with compensated advanced chronic liver disease—authors' reply

Yu‐Jie Zhou,Ming‐Hua Zheng

DOI: https://doi.org/10.1111/apt.16528

2021-07-31

Abstract:This article is linked to Zhou et al and Wong papers. To view these articles, visit https://doi.org/10.1111/apt.16487 and https://doi.org/10.1111/apt.16507

pharmacology & pharmacy,gastroenterology & hepatology

What problem does this paper attempt to address?

Editorial: Time to Eat? Skipping Breakfast in Metabolic-Associated Fatty Liver Disease-Authors' Reply.

Jiarong Xie,Lei Xu,Chengfu Xu

DOI: https://doi.org/10.1111/apt.16773

IF: 9.524

2022-01-01

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENTThis article is linked to Xie et al papers. To view these articles, visit https://doi.org/10.1111/apt.16727 and https://doi.org/10.1111/apt.16755
Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply

Eunice X. X. Tan,Daniel Q. Huang,Mindie H. Nguyen

DOI: https://doi.org/10.1111/apt.18112

IF: 9.524

2024-06-14

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Eunice et al papers. To view these articles, visit https://doi.org/10.1111/apt.17914 and https://doi.org/10.1111/apt.17951

pharmacology & pharmacy,gastroenterology & hepatology
Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis

Changzhou Cai,Xin Song,Xueyang Chen,Weihua Zhou,Qi Jin,Shenghui Chen,Feng Ji

DOI: https://doi.org/10.1155/2021/8859338

IF: 29.4

2021-01-01

Gastroenterology

Abstract:Background and Aims. Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) have become common chronic liver diseases. Recent evidence has shown the value of transient elastography (TE) in the context of ALD/NAFLD. The aim of this study is to investigate the accuracy of TE for diagnosing steatosis and fibrosis in ALD/NAFLD patients. Methods. We retrieved relevant English studies from the databases of PubMed, Embase, the Web of Science, and the Cochrane Library through March 31(st) 2019. We included studies regarding the diagnosis or staging of steatosis or fibrosis by using controlled attenuation parameter (CAP) or liver stiffness measurement (LSM) measured by TE in patients with ALD or NAFLD. The reference standard of all included studies was liver biopsy. A random-effects model was applied. Statistical analyses were performed using STATA. Results. A total of 62 articles were included and analyzed in our meta-analysis. In patients with ALD/NAFLD, the pooled results revealed that the sensitivity and specificity of CAP were 0.84, 0.83, and 0.78 and 0.83, 0.71, and 0.62 for steatosis grades >= S1, >= S2, and =S3, respectively. The sensitivity and specificity of LSM for identifying fibrosis grades >= F1, >= F2, >= F3, and =F4 were 0.77, 0.77, 0.83, and 0.91 and 0.80, 0.82, 0.84, and 0.86, respectively. Conclusion. In patients with ALD/NAFLD, CAP was feasible for identifying and screening steatosis, and LSM was accurate for diagnosing fibrosis, especially severe fibrosis and cirrhosis.
[Research Advances in Diagnosis of Non-Alcoholic Fatty Liver Disease].

J H Wang,C H Yu

DOI: https://doi.org/10.3760/cma.j.issn.1007-3418.2017.02.007

2017-01-01

Abstract:Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in clinical practice, and the spectrum of NAFLD includes nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, and liver cirrhosis. Some patients may even progress to hepatocellular carcinoma. At present, the gold standard for the diagnosis of NAFLD is liver biopsy, but since this is an invasive examination and has high costs, its application is limited in clinical practice. More and more studies have focused on noninvasive diagnostic methods for NAFLD, including serological markers, fatty liver predictive model, and imaging examinations. Emerging diagnostic techniques, including genomics, proteomics, glycomics, and metabolomics, also play an important role in the diagnosis of NAFLD.
A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease

Qing Gu,Li Cen,Jiawei Lai,Zhongchen Zhang,Jiaqi Pan,Feng Zhao,Chaohui Yu,Youming Li,Chunxiao Chen,Weixing Chen,Zhe Shen

DOI: https://doi.org/10.1111/eci.13446

2021-01-01

European Journal of Clinical Investigation

Abstract:Background Noninvasive methods have been used for the assessment of hepatic steatosis in patients with nonalcoholic fatty liver disease (NAFLD). The aim was to assess the efficacy and accuracy of both magnetic resonance imaging(MRI) and transient elastography(TE) for the evaluation of hepatic steatosis. Materials and Methods The PubMed, Cochrane Library, Embase, MEDLINE and Web of Science databases were searched to retrieve studies examining the accuracy of MRI-proton density fat fraction(PDFF) and TE-controlled attenuation parameter(CAP) for evaluating the grading of steatosis(S0-S3) diagnosed by liver biopsy in NAFLD. We compared the sensitivity, specificity, hierarchical summary receiver operating characteristic curves(HSROC) and clinical utility of these methods. Results Twenty-four articles with a total of 2979 patients with NAFLD were included. The steatosis distribution was 8.1%/35.1%/32.2%/24.6% for S0/S1/S2/S3. For the diagnostic accuracy of MRI-PDFF, the HSROCs were 0.97 for >= S1, 0.91 for >= S2 and 0.90 for >= S3. For the diagnostic accuracy of TE-based CAP, the HSROCs were 0.85 for >= S1, 0.83 for >= S2 and 0.79 for >= S3. Following a 'positive' measurement (over the threshold value) for >= S1, the corresponding post-test probabilities of PDFF and CAP for the presence of steatosis were 82% and 61%, respectively, when the pretest probability was 24%. If the values were below these thresholds ('negative' results), the post-test probabilities were 3% and 7%. Conclusion MRI-PDFF and TE-CAP both provide highly accurate noninvasive approaches for quantifying and staging hepatic steatosis in NAFLD. Compared with TE-CAP, MRI-PDFF is significantly more accurate for evaluating dichotomized grades of steatosis.
Guidelines for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Diseases

Min De Zeng,You Ming Li,Cheng Wei Chen,Lun Gen Lu,Jian Gao Fan,Bing Yuan Wang,Yi Min Mao

DOI: https://doi.org/10.1111/j.1751-2980.2008.00331.x

2008-01-01

Journal of Digestive Diseases

Abstract:Journal of Digestive DiseasesVolume 9, Issue 2 p. 108-112 Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases* Min De ZENG, Min De ZENG Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this authorJian Gao FAN, Jian Gao FAN Department of Gastroenterology, Shanghai First People's Hospital, Jiaotong University, Shanghai,Search for more papers by this authorLun Gen LU, Lun Gen LU Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this authorYou Ming LI, You Ming LI Department of Gastroenterology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,Search for more papers by this authorCheng Wei CHEN, Cheng Wei CHEN Clinical Center for Hepatology, No. 85 Army Hospital, Shanghai,Search for more papers by this authorBing Yuan WANG, Bing Yuan WANG Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang, ChinaSearch for more papers by this authorYi Min MAO, Yi Min MAO Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this author Min De ZENG, Min De ZENG Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this authorJian Gao FAN, Jian Gao FAN Department of Gastroenterology, Shanghai First People's Hospital, Jiaotong University, Shanghai,Search for more papers by this authorLun Gen LU, Lun Gen LU Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this authorYou Ming LI, You Ming LI Department of Gastroenterology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,Search for more papers by this authorCheng Wei CHEN, Cheng Wei CHEN Clinical Center for Hepatology, No. 85 Army Hospital, Shanghai,Search for more papers by this authorBing Yuan WANG, Bing Yuan WANG Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang, ChinaSearch for more papers by this authorYi Min MAO, Yi Min MAO Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this author First published: 16 April 2008 https://doi.org/10.1111/j.1751-2980.2008.00331.xCitations: 123 : Min De ZENG, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200001, China. Email: xhsyljd@yahoo.com.cn * The Chinese National Consensus Workshop on nonalcoholic fatty liver diseases was organized by Chinese Society of Hepatology, Chinese Medical Association. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume9, Issue2May 2008Pages 108-112 RelatedInformation
Editorial: Liver elastography for chronic hepatitis D—the end of liver biopsy?

María Buti,Adriana Palom,Mar Riveiro‐Barciela

DOI: https://doi.org/10.1111/apt.17890

IF: 9.524

2024-03-12

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 7, Page 898-899, April 2024.

pharmacology & pharmacy,gastroenterology & hepatology
LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Qingmin Zeng,Chang-Hai Liu,Dongbo Wu,Wei Jiang,Nannan Zhang,Hong Tang

DOI: https://doi.org/10.3390/biom13030560

IF: 6.064

2023-03-21

Biomolecules

Abstract:Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide. Early identification and prompt treatment are critical to optimize patient management and improve long-term prognosis. Long non-coding RNA (lncRNA) and circular RNA (circRNA) are recently emerging non-coding RNAs, and are highly stable and easily detected in the circulation, representing a promising non-invasive approach for predicting NAFLD. A literature search of the Pubmed, Embase, Web of Science, and Cochrane Library databases was performed and 36 eligible studies were retrieved, including 18 on NAFLD, 13 on nonalcoholic steatohepatitis (NASH), and 11 on fibrosis and/or cirrhosis. Dynamic changes in lncRNA expression were associated with the occurrence and progression of NAFLD, among which lncRNA NEAT1, MEG3, and MALAT1 exhibited great potential as biomarkers for NAFLD. Moreover, mitochondria-located circRNA SCAR can drive metaflammation and its inhibition might be a promising therapeutic target for NASH. In this systematic review, we highlight the great potential of lncRNA/circRNA for early diagnosis and progression assessment of NAFLD. To further verify their clinical value, large-cohort studies incorporating lncRNA and circRNA expression both in liver tissue and blood should be conducted. Additionally, detailed studies on the functional mechanisms of NEAT1, MEG3, and MALAT1 will be essential for elucidating their roles in diagnosing and treating NAFLD, NASH, and fibrosis.

biochemistry & molecular biology
Serum Proteomic Analysis Revealed Diagnostic Value of Hemoglobin for Nonalcoholic Fatty Liver Disease

Chaohui Yu,Chengfu Xu,Lei Xu,Jiekai Yu,Min Miao,Youming Li

DOI: https://doi.org/10.1016/j.jhep.2011.05.027

IF: 25.7

2012-01-01

Journal of Hepatology

Abstract:Background & Aims: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. The two linked studies presented herein aimed to identify and verify new biomarkers for NAFLD.Methods: First, 70 serum samples were analyzed using proteomics approaches to identify potential biomarkers for NAFLD. Second, a total of 6944 initial NAFLD-free subjects were followed up for 3 years to evaluate the predictive value of hemoglobin for NAFLD.Results: In the first study, 20 differentially expressed protein peaks (11 up-regulated and nine down-regulated) were observed in NAFLD patients upon comparison to the controls. With the aid of bioinformatic tools, we established a biomarker pattern for NAFLD with a sensitivity of 89% and a specificity of 83%. Further analysis suggested a protein peak to be hemoglobin subunit alpha. In the second study, prospective analysis showed that subjects with higher baseline hemoglobin levels were associated with higher incidence of NAFLD. Cox proportional hazards regression analyses showed that the age, gender, and body mass index adjusted hazard ratio (95% CI) for subjects with baseline hemoglobin level in quintile 2, 3, 4, and 5 vs. quintile 1 was 1.36 (1.02-1.81), 1.66 (1.23-2.25), 1.76 (1.28-2.41), and 1.83 (1.33-2.53), respectively.Conclusions: Our study showed that serum hemoglobin may have significant predictive value for NAFLD. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Editorial: Redrawing the Boundaries for Surgical Intervention in Hepatocellular Carcinoma—authors’ Reply

Yan-Yan Wang,Jian-Hong Zhong,Yi-Lei Mao,Le-Qun Li,Bao-Cai Xing

DOI: https://doi.org/10.1111/apt.15142

IF: 9.524

2019-01-01

Alimentary Pharmacology & Therapeutics

Abstract:Linked Content This article is linked to Wang et al and Liem and Janssen papers. To view these articles, visit and .
Liver Ultrasound Elastography in Non-Alcoholic Fatty Liver Disease: A State-of-the-Art Summary

Rosanna Villani,Pierluigi Lupo,Moris Sangineto,Antonino Davide Romano,Gaetano Serviddio

DOI: https://doi.org/10.3390/diagnostics13071236

2023-03-24

Abstract:Non-alcoholic fatty liver disease (NAFLD) is a chronic disease which is currently the most common hepatic disorder affecting up to 38% of the general population with differences according to age, country, ethnicity and sex. Both genetic and acquired risk factors such as a high-calorie diet or high intake of saturated fats have been associated with obesity, diabetes and, finally, NAFLD. A liver biopsy has always been considered essential for the diagnosis of NAFLD; however, due to several limitations such as the potential occurrence of major complications, sampling variability and the poor repeatability in clinical practice, it is considered an imperfect option for the evaluation of liver fibrosis over time. For these reasons, a non-invasive assessment by serum biomarkers and the quantification of liver stiffness is becoming the new frontier in the management of patients with NAFLD and liver fibrosis. We present a state-of-the-art summary addressing the methods for the non-invasive evaluation of liver fibrosis in NAFLD patients, particularly the ultrasound-based techniques (transient elastography, ARFI techniques and strain elastography) and their optimal cut-off values for the staging of liver fibrosis.
Response to letter regarding "LASSO-derived model for the prediction of lean-non-alcoholic fatty liver disease in examinees attending a routine health check-up"

Chiao-Lin Hsu,Hsien-Chung Yu,Fu-Zong Wu

DOI: https://doi.org/10.1080/07853890.2024.2357228

IF: 5.348

2024-05-26

Annals of Medicine

Abstract:Dear Dr. Zhang and Dr. Li, Thank you for your insightful comments and constructive critique of our research. We greatly appreciate the opportunity to address your concerns and provide further clarification.

medicine, general & internal
Recent advances in NAFLD: current areas of contention

Erica Jennison,Christopher D Byrne

DOI: https://doi.org/10.12703/r/12-10

2023-05-02

Abstract:This brief review focuses on two contentious issues within the field of non-alcoholic fatty liver disease (NAFLD); the first is the recent effort to redefine NAFLD as metabolic (dysfunction)-associated fatty liver disease (MAFLD). The modification of "NAFLD" to "MAFLD" is expected to highlight the role of metabolic factors in the disease aetiology, which is hoped to improve patient understanding of the disease, facilitate patient-physician communication and highlight the importance of public health interventions in prevention and management. The diagnostic criteria for MAFLD allow it to coexist with other forms of liver disease, which recognises that metabolic dysfunction contributes towards disease progression in other liver pathologies, such as alcoholic liver disease. However, there remain concerns that renaming NAFLD may be premature without fully considering the broader implications, from diagnostic criteria to trial endpoints; therefore, the new definition has not yet been accepted by major societies. Another contentious issue within the field is the gap in our understanding of how patients undergoing therapeutic interventions should be monitored to assess amelioration/attenuation or the worsening of their liver disease. Biomarker scoring systems (such as the ELF test and FIB-4 test) and imaging techniques (such as transient elastography [TE] and magnetic resonance imaging [MRI] techniques) are proven to be reasonably accurate, and comparable with histology, in the diagnosis of NAFLD and evaluation of disease severity; however, their use in monitoring the response of disease to therapeutic interventions is not well established. Whilst biomarker scoring systems and TE are limited by poor diagnostic accuracy in detecting moderate fibrosis (e.g. F2 liver fibrosis defined by histology), more accurate MRI techniques are not practical for routine patient follow-up due to their expense and limited availability. More work is required to determine the most appropriate method by which therapeutic interventions for NAFLD should be monitored in clinical practice.
Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease: Authors' reply

Bernhard Scheiner,Nina Dominik,Mattias Mandorfer

DOI: https://doi.org/10.1111/apt.18144

IF: 9.524

2024-07-03

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Dominik et al papers. To view these articles, visit https://doi.org/10.1111/apt.17945 and https://doi.org/10.1111/apt.18066

pharmacology & pharmacy,gastroenterology & hepatology
Letter: improved alanine aminotransferase level in non-cirrhotic and low-viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues -authors' reply

Rui Huang,Jian Wang,Xiaomin Yan,Chuanwu Zhu,Chao Wu

DOI: https://doi.org/10.1111/apt.17367

IF: 9.524

2023-01-01

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Wang et al papers. To view these articles, visit https://doi.org/10.1111/apt.17272 and https://doi.org/10.1111/apt.17329
Pitfalls in the Non-Invasive Assessment of Liver Fibrosis with Elift-Fmvcte Algorithm

Xiao-Chen Wang,Xiao-Yu Zhang,Xin Zhang,Zhao-Xin Yuan,Xiu-Hui Li,Jin-Cheng Wang,Beicheng Sun,Xiao-Jie Lu

DOI: https://doi.org/10.1016/j.jhep.2017.08.038

IF: 25.7

2018-01-01

Journal of Hepatology

Abstract:We read with interest the study by Boursier et al. titled “A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis” recently published in the Journal.[1] Boursier J. de Ledinghen V. Leroy V. Anty R. Francque S. Salmon D. et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017; 66: 1158-1165 Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar Using liver biopsy as reference in a cross-sectional study, the authors developed a stepwise algorithm for the detection of advanced liver fibrosis. This algorithm comprised of a first-line test called easy liver fibrosis test (eLIFT), followed by a second-line test of FibroMeter plus vibration controlled transient elastography (FMVCTE). When tested in a longitudinal cohort of 1,275 patients, the eLIFT-FMVCTE algorithm showed promising prognostic performance. This algorithm provides a potential method to extend the detection of advanced liver fibrosis to all chronic liver disease patients and to reduce unnecessary referrals of patients without significant fibrosis to hepatologists. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosisJournal of HepatologyVol. 66Issue 6PreviewChronic liver diseases (CLD) are very common: worldwide, an estimated 160 million people have chronic hepatitis C [1], 240 million have chronic hepatitis B [2], and 25% of the general population has non-alcoholic fatty liver disease (NAFLD) [3]. CLD can lead to a progressive accumulation of fibrosis in the liver which progressively evolves to cirrhosis and its life-threatening complications such as hepatocellular carcinoma (HCC), liver failure, variceal bleeding, or renal insufficiency. In 2012, driven by the growing worldwide burden of CLD, cirrhosis was responsible for more than 35 million years of lost life and thus became the eleventh leading cause of mortality among non-communicable diseases [4]. Full-Text PDF Reply to: “Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FMVCTE algorithm” and to “Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes”Journal of HepatologyVol. 68Issue 3PreviewScreening of advanced liver fibrosis: one step at a time Full-Text PDF
Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States—Authors' reply

Samer Gawrieh,Mark Sulkowski,Naga Chalasani,Rohit Loomba

DOI: https://doi.org/10.1111/apt.17886

IF: 9.524

2024-02-26

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 6, Page 791-791, March 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance: Authors' reply

Sally Tran,Linda Henry,Mindie H. Nguyen

DOI: https://doi.org/10.1111/apt.18265

IF: 9.524

2024-09-11

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Tran et al papers. To view these articles, visit https://doi.org/10.1111/apt.18024 and https://doi.org/10.1111/apt.18245 .

pharmacology & pharmacy,gastroenterology & hepatology
Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply

Tarek Hassanein,Andrew P. Keaveny,Parvez Mantry,Alastair D. Smith,Michael P. McRae,John Kittelson,Steve Helmke,Gregory T. Everson,for the SHUNT‐V Investigators

DOI: https://doi.org/10.1111/apt.18128

IF: 9.524

2024-06-27

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Hassanein et al papers. To view these articles, visit https://doi.org/10.1111/apt.18054 and https://doi.org/10.1111/apt.18113

pharmacology & pharmacy,gastroenterology & hepatology
Editorial: Considerations for Expanding Treatment in Grey Zone Chronic Hepatitis B Patients-Authors' Reply.

Rui Huang,Jian Wang,Xiaomin Yan,Chuanwu Zhu,Chao Wu

DOI: https://doi.org/10.1111/apt.17369

IF: 9.524

2023-01-01

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Wang et al papers. To view these articles, visit https://doi.org/10.1111/apt.17272 and https://doi.org/10.1111/apt.17340

Editorial: an elastography‐based two‐step approach to detect NAFLD with compensated advanced chronic liver disease—authors' reply

Editorial: Time to Eat? Skipping Breakfast in Metabolic-Associated Fatty Liver Disease-Authors' Reply.

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply

Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis

[Research Advances in Diagnosis of Non-Alcoholic Fatty Liver Disease].

A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease

Guidelines for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Diseases

Editorial: Liver elastography for chronic hepatitis D—the end of liver biopsy?

LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Serum Proteomic Analysis Revealed Diagnostic Value of Hemoglobin for Nonalcoholic Fatty Liver Disease

Editorial: Redrawing the Boundaries for Surgical Intervention in Hepatocellular Carcinoma—authors’ Reply

Liver Ultrasound Elastography in Non-Alcoholic Fatty Liver Disease: A State-of-the-Art Summary

Response to letter regarding "LASSO-derived model for the prediction of lean-non-alcoholic fatty liver disease in examinees attending a routine health check-up"

Recent advances in NAFLD: current areas of contention

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease: Authors' reply

Letter: improved alanine aminotransferase level in non-cirrhotic and low-viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues -authors' reply

Pitfalls in the Non-Invasive Assessment of Liver Fibrosis with Elift-Fmvcte Algorithm

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States—Authors' reply

Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance: Authors' reply

Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply

Editorial: Considerations for Expanding Treatment in Grey Zone Chronic Hepatitis B Patients-Authors' Reply.